Trudhesa Spray, Metered
Product Images NDC 77530-725

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Trudhesa (NDC 77530-725). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Impel Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Trudhesa 01)

Chemical structure diagram of dihydroergotamine mesylate, the active ingredient in Trudhesa nasal spray. The image shows the molecular framework with labeled functional groups and the mesylate component (CH3SO3H).*

FDA Label Image

Figure 1 (Trudhesa 02)

A line graph comparing the estimated probability of response to study medication over time between Dihydroergotamine Mesylate and placebo groups from Studies 1 and 2. The x-axis shows time from first dose in hours (0 to 4), and the y-axis shows estimated response probability percentage (0 to 100%). The Dihydroergotamine Mesylate group shows a higher response probability than placebo throughout the 4-hour period.*

FDA Label Image

Figure 2 (Trudhesa 03)

A line graph depicting the estimated probability of response to study medication (%) over time from first dose (hours) in Studies 3 and 4. It compares Dihydroergotamine Mesylate and Placebo in participants (97 and 100 respectively), showing a higher response probability with Dihydroergotamine Mesylate increasing steadily over 4 hours compared to Placebo.*

FDA Label Image

Figure 3 (Trudhesa 04)

A line graph comparing the estimated probability of analgesic use over 24 hours after first spray between Dihydroergotamine Mesylate (N=305) and placebo (N=300). The x-axis shows hours after first spray (0 to 24), and the y-axis shows percentage probability (0% to 100%). The placebo line increases more steeply and reaches a higher probability than the Dihydroergotamine Mesylate line.*

FDA Label Image

Image (Trudhesa 05)

The image shows the primary labeling of Trudhesa spray, metered nasal dosage form containing 4 mg/mL dihydroergotamine mesylate. The label includes the proprietary name Trudhesa prominently, with the generic name and dosage form indicated. The product is labeled as a human prescription drug and is manufactured by Impel Pharmaceuticals LLC. A QR code is also visible on the label.*

FDA Label Image

Figure (Trudhesa 06)

The image shows the Trudhesa nasal spray packaging by Impel Pharmaceuticals LLC. It includes a dosing instruction booklet, a small bottle labeled Trudhesa (dihydroergotamine mesylate) 4 mg/mL, and a white, handheld metered spray device designed for nasal administration. The components are housed in a white, molded plastic case.*

FDA Label Image

Figure (Trudhesa 07)

An instructional diagram of the Trudhesa nasal metered spray device showing labeled parts: Spray Nozzle at the top, Finger Grips on the sides, Plastic Pump at the bottom, and a Clear Plastic Cover that fits over the pump.*

FDA Label Image

Figure (Trudhesa 08)

Illustration showing the component parts of a Trudhesa nasal spray bottle containing dihydroergotamine mesylate 4 mg/mL. The labeled parts include a blue plastic cover, metal foil sealing, grey rubber stopper, and a glass vial with a visible label indicating the product name and strength.*

FDA Label Image

Figure A (Trudhesa 09)

An instructional diagram showing a Trudhesa nasal spray bottle being placed into a refrigerator. The image illustrates proper storage of Trudhesa (dihydroergotamine mesylate) spray, metered, 4 mg/mL by Impel Pharmaceuticals LLC.*

FDA Label Image

Figure B (Trudhesa 10)

An instructional illustration showing a person administering Trudhesa (dihydroergotamine mesylate) spray nasally. The image includes a close-up of a brown spray bottle labeled with Trudhesa and dosage 0.725 mg per spray, indicating nasal route administration.*

FDA Label Image

Figure C (Trudhesa 11)

An instructional illustration showing a close-up of a human eye and a small spray vial labeled 'FOR NASAL USE ONLY' with lot number and expiration date information. The image highlights where to find the lot and expiration date on the vial, emphasizing proper identification of the product for nasal administration.*

FDA Label Image

Figure D (Trudhesa 12)

An instructional illustration showing a hand lifting the tamper-evident seal off the top of a small brown glass vial, demonstrating how to open the vial correctly.*

FDA Label Image

Figure E (Trudhesa 13)

An instructional diagram illustrating the use of the Trudhesa nasal spray device. It shows a hand manipulating the device by pressing down on a circular component to administer the spray. The device appears to be designed for metered nasal delivery.*

FDA Label Image

Figure F (Trudhesa 14)

An instructional illustration showing a person removing the black cap from a brown nasal spray bottle, indicating the first step in using the Trudhesa nasal spray, dosed at 4 mg/mL, by Impel Pharmaceuticals LLC.*

FDA Label Image

Figure G (Trudhesa 15)

The image shows a brown glass bottle labeled Trudhesa, containing dihydroergotamine mesylate nasal spray with a strength of 4 mg/mL. The label includes the proprietary name Trudhesa, the generic name, and the manufacturer Impel Pharmaceuticals LLC. The bottle is designed for metered nasal spray use.*

FDA Label Image

Figure H (Trudhesa 16)

An instructional illustration showing a hand holding a Trudhesa nasal spray device above a cap. The image indicates aligning the device with the cap for attachment or detachment, demonstrated by a downward arrow. This diagram likely illustrates proper use or handling of the metered nasal spray.*

FDA Label Image

Figure I (Trudhesa 17)

An instructional illustration showing hands holding and pulling apart the white plastic actuator and the amber glass bottle of Trudhesa nasal spray, demonstrating how to detach the spray bottle from the actuator. A black arrow points upward, indicating the direction to remove the bottle.*

FDA Label Image

Figure J (Trudhesa 18)

An instructional diagram showing how to prepare the Trudhesa nasal spray device. The image illustrates a hand holding the spray bottle while another hand twists the base of the container to unlock or activate the metered spray mechanism.*

FDA Label Image

Figure K (Trudhesa 19)

An instructional diagram illustrating how to prime the Trudhesa nasal spray device containing dihydroergotamine mesylate 4 mg/mL. It shows a hand pressing down and then releasing the spray nozzle, with text instructing to pump exactly 4 times to prime the device before use. The spray is directed toward a profile of a person's face.*

FDA Label Image

Figure L (Trudhesa 20)

Instructional illustration showing a person using Trudhesa nasal spray, metered dose. The image highlights holding the device upright and keeping the head straight during administration, with the spray nozzle positioned at the nostril.*

FDA Label Image

Figure M (Trudhesa 21)

Instructional diagram showing how to use Trudhesa (Dihydroergotamine mesylate) 4 mg/mL nasal spray. It depicts a hand holding the spray device, indicating to press down with the index and middle fingers on the nasal applicator while pressing up with the thumb on the bottom. The nose illustration shows spraying once into one nostril.*

FDA Label Image

Figure N (Trudhesa 22)

Instructional diagram demonstrating the use of Trudhesa 4 mg/mL nasal spray, metered dose. It shows a person holding the spray, pressing down on the top to release the medication into the nostril, with arrows indicating the direction of pressing. The diagram includes a note to spray one time per use.*

FDA Label Image

Figure O (Trudhesa 23)

An instructional illustration showing a hand holding a Trudhesa nasal spray and disposing of the spray container into a trash receptacle labeled 'TRASH'. The image indicates proper disposal of the used nasal spray device.*

FDA Label Image

Principal Display Panel (0.725 mg Vial Carton)

Trudhesa nasal spray packaging label for dihydroergotamine mesylate, 0.725 mg per spray. The carton includes dosage instructions referencing prescribing information and states it contains 4 nasal spray devices and 4 Trudhesa vials. Manufactured for Impel NeuroPharma, with manufacturer information for Mipharm S.p.A., Milan, Italy. The label includes storage instructions and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.